熱門資訊> 正文
Immedica收购Marinus Pharmaceuticals，股价上涨4%
2024-12-30 20:08
- Immedica Pharma AB, a global rare disease company will acquire Marinus Pharmaceuticals (NASDAQ:MRNS) by means of a tender offer and subsequent merger.
- The acquisition complements and further strengthens Immedica’s global rare disease business.
- Immedica, through a wholly owned, direct subsidiary, will initiate a tender offer to acquire all shares of Marinus for a cash purchase price of $0.55 per share, representing a premium of 48% based on Marinus’ closing share price as of December 27.
- The transaction is expected to close in Q1 2025.
- The stock price jumped 4.1% on Monday during re-market hours of trading.
More on Marinus Pharmaceuticals
- Marinus Pharmaceuticals GAAP EPS of -$0.42 in-line, revenue of $8.54M misses by $0.81M
- Marinus downgraded after setback to late-stage trial
- Seeking Alpha’s Quant Rating on Marinus Pharmaceuticals
- Historical earnings data for Marinus Pharmaceuticals
- Financial information for Marinus Pharmaceuticals
推薦文章
一周財經日曆 | 超重磅！英偉達、阿里、拼多多財報輪番；美國7月PCE數據來襲
美股機會日報 | 倒計時開始！市場屏息以待鮑威爾講話；中概股名創優品漲超8%，拼多多漲超4%
一周IPO丨雙登股份下周上市，超額認購逾3000倍；佳鑫國際資源火熱招股中
AH股追蹤丨上證指數一舉突破3800點！中芯國際A股飆漲14%，H股漲逾9%
港股異動 | 中興通訊H股午后持續拉昇！盤中漲超13%創歷史新高
華盛早報 | 韓國股民瘋買港股，外資傳大消息，做多中國熱情持續攀升；標普「五連陰」！今晚華爾街枕戈以待
美股機會日報 | 關税税率最高15%！美歐敲定框架貿易協議；何小鵬增持310萬股，小鵬汽車盤前股價漲超5%
一圖看懂 | 嗶哩嗶哩Q2營收73億元！上半年手遊收入大增68%，經調淨利潤同比扭虧為盈5.6億元
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
